Imagine a world where life-saving medications are no longer out of reach for millions of Americans. That's the bold vision President Donald Trump is pushing with his latest move: expanding the ‘Most Favored Nation’ (MFN) pricing deals to nine additional pharmaceutical giants. But here's where it gets controversial—while the White House hails this as a game-changer for lowering drug costs, many experts remain skeptical about its real-world impact. Will these deals truly deliver the relief patients desperately need, or are they more symbolic than substantial? Let’s dive in.
On Friday, Trump announced new voluntary agreements with nine major drug companies, building on earlier deals with five others, including the makers of blockbuster weight-loss drugs. The MFN program demands that drugmakers price medications sold in the U.S. at the lowest rates available in comparable countries—a move aimed at tackling the skyrocketing cost of prescriptions. And this is the part most people miss: while the initiative sounds promising, it currently covers only a fraction of the drugs available in the U.S., leaving many to wonder if it will make a meaningful difference.
The companies involved—Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and Sanofi—produce medications used by hundreds of millions of Americans to treat conditions like cancer, diabetes, and heart disease. A senior administration official praised the industry’s shift from initial resistance to cooperation, calling MFN “an industry standard achieved in record time.”
Under these deals, drugmakers agree to sell medicines to Medicaid at MFN prices and launch new drugs in the U.S. at the same rate. They’ll also list certain primary care and specialty medicines on the upcoming TrumpRx online platform, launching in January. This platform will connect patients directly to drugmakers’ discounted offerings, bypassing insurance for those paying out of pocket. Additionally, the companies have pledged over $150 billion in U.S.-based manufacturing and R&D projects, earning them a three-year tariff reprieve on pharmaceutical imports.
Here’s where opinions start to clash: While Trump touts these agreements as major wins, critics argue they’re “largely inconsequential” to drugmakers’ bottom lines. Chris Meekins of Raymond James points out that the TrumpRx portal might only benefit those who can afford cash payments, as most Americans still find insurance coverage cheaper. The exception? GLP-1 drugs like Wegovy and Zepbound, often not covered by insurers for weight loss, which could drop to as low as $149 per month under recent deals.
Another point of contention: Several drugmakers have agreed to donate active pharmaceutical ingredients (APIs) to a national emergency stockpile, addressing national security concerns over imported APIs. However, experts caution that the lack of detailed information about these deals makes it hard to predict their long-term impact.
So, is this a groundbreaking step toward affordable healthcare, or a well-intentioned effort falling short? What do you think? Are these deals a significant stride forward, or do they need to go further? Share your thoughts in the comments—let’s spark a conversation that could shape the future of healthcare in America.
